HIMA acknowledges predominance of small firms:
This article was originally published in Clinica
Executive Summary
The numbers vary, but qualitative opinion acknowledges that the medical device industry is, in the words of one participant at HIMA's annual general meeting, a cottage industry. Received wisdom says that about 80% of medical device companies are small. Accepting this reality, HIMA has changed the cost of membership, allowing small companies to join for less than large companies, and has netted 63 new members. The organisation's president, Alan Magazine, has set up an office to support the interests of small companies.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.